Prostate cancer screening

IMVARIA Enters into Know-how Agreement with Mayo Clinic to Improve the Understanding of Cancer through AI Digital Biomarkers

Retrieved on: 
Wednesday, November 1, 2023

IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced a collaboration through a know-how agreement with Mayo Clinic to develop AI designed to significantly improve the analysis and understanding of cancer, beginning with lung cancer.

Key Points: 
  • IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced a collaboration through a know-how agreement with Mayo Clinic to develop AI designed to significantly improve the analysis and understanding of cancer, beginning with lung cancer.
  • The collaboration brings together IMVARIA’s engineering expertise in digital biomarkers with Mayo Clinic’s know-how and data assets as part of the Validate pillar of Mayo Clinic Platform.
  • In 2023, over 125,000 deaths have occurred due lung cancer, and nearly a quarter-of-a-million new lung cancer cases were identified.
  • Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.

Prostate Cancer Treatment can be safely delayed, and inexpensively and accurately monitored thanks to new Artificial Intelligence

Retrieved on: 
Tuesday, March 28, 2023

Therefore, biopsies are not an effective screening tool for prostate cancer, but are a confimatory tool if utilized with imaging guidance.

Key Points: 
  • Therefore, biopsies are not an effective screening tool for prostate cancer, but are a confimatory tool if utilized with imaging guidance.
  • In conclusion, bpMRI with CAD (AI) such as ProstatID, is poised to change the Standard of Care for Prostate Cancer screening, detection and diagnosis by avoiding the costly pitfalls of current prostate cancer pathways.
  • al., Fifteen-year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer, NEJM, March 11, 2023.
  • Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection.

Cleveland Diagnostics Announces Agreement with Quest Diagnostics to Expand Patient Access to IsoPSA® Prostate Cancer Testing

Retrieved on: 
Monday, February 13, 2023

Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, today announced an agreement designed to expand patient access to Cleveland Diagnostics’ novel prostate cancer test, IsoPSA.

Key Points: 
  • Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, today announced an agreement designed to expand patient access to Cleveland Diagnostics’ novel prostate cancer test, IsoPSA.
  • With its national logistics network, Quest will transport the specimens to Cleveland Diagnostics’ laboratory for testing.
  • The parties expect physicians will be able to begin offering the test to patients through Quest Diagnostics in the second quarter of 2023.
  • IsoPSA is a blood-based prostate cancer test used in triaging patients at risk for high-grade prostate cancer to biopsy.

PROSTATE CANCER POSES AN INCREASING THREAT TO MEN

Retrieved on: 
Tuesday, January 17, 2023

DENVER, Jan. 16, 2023 /PRNewswire/ -- Recent data highlights a worrisome prostate cancer risk for men and even greater concern for men in select racial groups. The American Cancer Society projects more than 288,000 men will be diagnosed with prostate cancer this year and nearly 35,000 men will die from the disease making it once again the most diagnosed cancer in men and the second leading cause of cancer death for men.

Key Points: 
  • The American Cancer Society projects more than 288,000 men will be diagnosed with prostate cancer this year and nearly 35,000 men will die from the disease making it once again the most diagnosed cancer in men and the second leading cause of cancer death for men.
  • "Not only is the incidence of prostate cancer increasing, but we are also sadly finding more cases of advanced prostate cancer when its advanced", stated PCEC Founder and Chairman E. David Crawford, MD.
  • For over 35 years the Prostate Conditions Education Council (PCEC), a national non-profit organization committed to men's health and a leader in prostate cancer screening, has provided free prostate cancer and men's health testing contributing to a 53% decrease in the risk of dying from prostate cancer.
  • Men should undergo prostate cancer screening by age 50 and age 45 for Black men and those who have a family history of the disease.

Micronoma Receives FDA Breakthrough Device Designation for OncobiotaLUNG, A Novel Liquid Biopsy Assay for Lung Carcinoma Detection

Retrieved on: 
Tuesday, January 10, 2023

Micronoma , the first biotech company offering early cancer detection with a microbiome-driven liquid biopsy platform, announced today that its OncobiotaLUNG assay received the Breakthrough Device Designation from the Food and Drug Administration (FDA).

Key Points: 
  • Micronoma , the first biotech company offering early cancer detection with a microbiome-driven liquid biopsy platform, announced today that its OncobiotaLUNG assay received the Breakthrough Device Designation from the Food and Drug Administration (FDA).
  • As a result, Micronoma can expect continued guidance and prioritized reviews from the agency of its upcoming clinical trial and concomitant pre-market approval processes.
  • Early detection of lung cancer can lead to a higher survival rate.
  • “Receiving FDA Breakthrough Device Designation is a fantastic recognition by the agency and a great milestone for Micronoma,” said Sandrine Miller-Montgomery, Micronoma CEO and co-founder.

Early Is Good Raises $4 Million Seed Round from Social Capital

Retrieved on: 
Wednesday, November 2, 2022

Early is Good (EIG), a diagnostic solutions company focused on renal disease, announced it has closed a $4 million seed round from Social Capital, the Silicon Valley-based technology investment firm managed by Chamath Palihapitiya.

Key Points: 
  • Early is Good (EIG), a diagnostic solutions company focused on renal disease, announced it has closed a $4 million seed round from Social Capital, the Silicon Valley-based technology investment firm managed by Chamath Palihapitiya.
  • The funds will be used to complete clinical trials for EIGs first product, BCDx, a lab-developed test (LDT) for early bladder cancer detection.
  • Social Capital partner, Jay Zaveri, said, EIG hopes to give millions of people access to accurate, convenient, and early diagnoses for renal diseases.
  • Social Capital invests in smart, profit-minded opportunities and forward-thinking social investments that have the potential to shape a better future.

Nonagen Bioscience announces Wayne Hogrefe, PhD as chief operating officer (COO)

Retrieved on: 
Tuesday, June 7, 2022

LOS ANGELES, June 7, 2022 /PRNewswire/ -- Nonagen Bioscience, a cancer diagnostics company, today announced that Wayne Hogrefe, PhD, has been named COO.

Key Points: 
  • LOS ANGELES, June 7, 2022 /PRNewswire/ -- Nonagen Bioscience, a cancer diagnostics company, today announced that Wayne Hogrefe, PhD, has been named COO.
  • He will also work closely with the US Food and Drug Administration (FDA) as Nonagen seeks FDA approval of Oncuria as an in vitro diagnostic (IVD).
  • "Wayne is the perfect leader to help us bring our first diagnostic to market," said Nonagen Bioscience CEO Charles Joel Rosser, MD, MBA.
  • Nonagen Bioscience is a privately held biotechnology company that is focused on globally reducing the burden of cancer with innovative diagnostics.

Pieces Partners with NRG Oncology to Accelerate Identification of Patients for Clinical Trial on Colorectal Cancer Prevention

Retrieved on: 
Tuesday, June 7, 2022

DALLAS, June 7, 2022 /PRNewswire/ -- Pieces, a healthcare AI company, has been chosen as the technology partner for NRG Oncology's FORTE study to accelerate the identification of participants eligible for a major clinical trial. Pieces will employ Pieces Predict, an analytics engine utilizing Natural Language Processing (NLP) and Artificial Intelligence (AI) to extract approved data from clinical notes and records to help identify participants who might qualify for the study. This AI-driven strategy is more efficient than traditional patient identification methods which are often manual, time-consuming, and costly for clinical trial sites.

Key Points: 
  • This AI-driven strategy is more efficient than traditional patient identification methods which are often manual, time-consuming, and costly for clinical trial sites.
  • NCORP is a national network of investigators and cancer care providers that conduct multisite cancer clinical trials in prevention, screening, symptom management, and cancer care delivery.
  • The trial is being led by NRG Oncology with the participation of other network organizations: Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and SWOG.
  • The NRG NCORP focuses on cancer prevention and control, cancer care delivery, health disparities and patient reported outcomes.

IND approval from the US FDA for Phase II SAR-Bombesin imaging trial in prostate cancer

Retrieved on: 
Monday, June 6, 2022

SYDNEY, June 6, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address growing medical needs in oncology, announces the approval of its Investigational New Drug (IND) application by the United States Food and Drug Administration (US FDA) to evaluate its SAR-Bombesin product as an imaging agent in prostate cancer patients that are Prostate-Specific Membrane Antigen (PSMA)-negative.

Key Points: 
  • Clarity's Executive Chairman, Dr Alan Taylor, commented,"Receiving clearance from the FDA on the imaging trial with SAR-Bombesin is yet another significant milestone for Clarity.
  • SABRE, which derives from "Copper-64 SAR-Bombesin in Biochemical REcurrence of Prostate Cancer trial", is a multi-center, single arm, non-randomised, open-label trial in up to 50 PSMA-negative patients with known or suspected prostate cancer.
  • The primary objectives of the trial are to investigate the safety and tolerability of 64Cu SAR-Bombesin, as well as its ability to correctly detect the recurrence of prostate cancer.
  • Given the prostate cancer indication is one of the largest in oncology, there is a significant unmet medical need in this segment.

Cleveland Diagnostics Announces Inclusion of IsoPSA® in National Comprehensive Cancer Network® Guidelines for Prostate Cancer Early Detection

Retrieved on: 
Wednesday, May 11, 2022

Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection (version 1.2022).

Key Points: 
  • Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection (version 1.2022).
  • We are honored that NCCN, an organization that provides valuable guidelines based on the latest evidence and expert consensus, now includes our IsoPSA test in its guidelines for prostate cancer early detection, said Arnon Chait, Ph.D., Chief Executive Officer at Cleveland Diagnostics.
  • Most urologists follow NCCN prostate cancer guidelines as a standard in the diagnosis and treatment of the disease, said Mark Stovsky, M.D., Chief Medical Officer at Cleveland Diagnostics.
  • Cleveland Diagnostics, Inc., is a commercial-stage biotechnology company developing highly efficacious, lab-friendly, affordable diagnostics tests using proprietary technology to improve cancer diagnostics.